What is ApiJect Systems?
ApiJect Systems operates at the intersection of medical device engineering and pharmaceutical manufacturing. The company specializes in the development of the ApiJect Platform, which enables biotech and pharmaceutical enterprises to design and deploy scalable, prefilled injectors. Utilizing Blow-Fill-Seal (BFS) technology, ApiJect provides a robust framework for high-volume, cost-effective drug delivery. This platform is designed to integrate seamlessly with both proprietary licensed packaging lines and third-party manufacturing partners, effectively addressing the global demand for rapid, reliable, and sterile injectable drug administration. By focusing on the fill-finish process, ApiJect mitigates common bottlenecks in the pharmaceutical production cycle, thereby enhancing the availability of life-saving treatments across diverse global markets.
How much funding has ApiJect Systems raised?
ApiJect Systems has raised a total of $111M across 1 funding round:
Other Financing Round
$111M
Other Financing Round (2022): $111M with participation from Royalty Pharma and Jefferies
Key Investors in ApiJect Systems
Royalty Pharma
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation, partnering with academic institutions and global pharmaceutical companies to co-fund late-stage clinical trials and product launches.
Jefferies
Jefferies Financial Group is a diversified investment banking and capital markets firm providing advisory services, debt financing, and underwriting to support corporate growth and strategic transactions.
What's next for ApiJect Systems?
With this major strategic investment, ApiJect Systems is poised to accelerate its operational footprint and deepen its integration into the global biopharmaceutical ecosystem. The company is expected to prioritize the expansion of its manufacturing capacity and the further refinement of its BFS technology to meet the rigorous demands of modern drug delivery. As the industry shifts toward more agile and decentralized production models, ApiJect's ability to provide scalable, high-quality injection solutions will likely serve as a cornerstone for future clinical and commercial product launches. The firm remains focused on its public-benefit mandate, aiming to bridge the gap between complex drug development and accessible patient care through technological innovation.
See full ApiJect Systems company page
